1.
Folkers K. Basic chemical research on coenzyme Q
10
and integrated clinical research on therapy of diseases. In Lenaz G, ed. Coenzyme Q. New York: John Wiley and Sons, 1985.
2.
Kishi T, Makino K, Okamoto T, et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q. In: International Symposium on Coenzyme Q. Biomedical and clinical aspects of coenzyme Q. Vol 2. New York, NY: Elsevier Science Publishing Co; 1980: 139-157.
3.
Palasciano G, et al. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long term treatment with psychotropic drugs.
Curr Ther Res
1994;55:537-545, 1994.
4.
Liu P, et al. Combined use of
Ginkgo biloba
extracts on efficacy and adverse reactions of various antipsychotics.
Zhongguo Linchuang Yaolixue Zaxhi.
1997;13:193-198.
5.
Adler LA, et al. Vitamin E treatment of tardive dyskinesia.
Am J Psychiatry.
1993;50:1405-1407.
6.
Adler LA, et al. Long term treatment effects of vitamin E for tardive dyskinesia.
Biol Psychiatry.
1998;43:868-872.
7.
Richardson MA. Amino acids in psychiatric disease. Washington, DC: American Psychiatric Press; 1990.
8.
Mosnik DM, Spring B, Rogers K, and Baruah SL. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients.
Neuropsychopharmacology
1997;16:136-146.
9.
Schelosky L, et al. Kava and dopamine antagonism.
J Neurol Neurosurg Psych
1995;58:639-640.
10.
Brinker F. Herb contraindications and drug interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications. 1998: 140-141.
11.
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B
6
in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Am J Psychiatry.
2001;158:1511-1514.
12.
Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.
J Clin Psychiatry
. 2001;62:878-883
13.
Lerner V, Bergman J, Statsenko N, et al. Vitamin B(6) treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
J Clin Psychiatry
. 2004;65:1550-1554.
14.
Nachshoni T, Ebert T, Abramovitch Y, et al. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial.
Schizophr Res
. 2005 Aug 25. [Epub ahead of print]
15.
Berger GE, Proffitt TM, McConchie M, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.
J Clin Psychiatry.
2007;68:1867-1875.
16.
Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia.
Schizophr Res.
2001;49:243-251.
17.
Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Am J Psychiatry.
2001;158:2071-2074.
18.
Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic Acid as supplemental treatment in schizophrenia.
Am J Psychiatry.
2002;159:1596-1598.
19.
Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Am J Psychiatry.
2001;158:2071-2074.
20.
Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results.
Prostaglandins Leukot Essent Fatty Acids.
2003;69:477-485.
21.
Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia.
Arch Gen Psychiatry.
1999;56:836-841.
22.
Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Arch Gen Psychiatry.
1999;56:29-36.
23.
Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Br J Psychiatry.
1996;169:610-617.
24.
Javitt DC, Zylberman I, Zukin SR, et al. Amelioration of negative symptoms in schizophrenia by glycine.
Am J Psychiatry.
1994;151:1234-1236.
Last reviewed April 2009 by EBSCO CAM Medical Review Board
Please be aware that this information is provided to supplement the care
provided by your physician. It is neither intended nor implied to be a
substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER
IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the
advice of your physician or other qualified health provider prior to
starting any new treatment or with any questions you may have regarding a
medical condition.
Copyright © 2007 HealthGate Data Corp. All rights reserved.